Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NASDAQ:IDXG

Interpace Biosciences (IDXG) Stock Price, News & Analysis

Interpace Biosciences logo

About Interpace Biosciences Stock (NASDAQ:IDXG)

Key Stats

Today's Range
$2.61
$2.70
50-Day Range
$4.75
$10.40
52-Week Range
$2.57
$10.42
Volume
2,649 shs
Average Volume
14,137 shs
Market Capitalization
$11.79 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Interpace Biosciences, Inc. provides molecular diagnostic tests, bioinformatics, and pathology services for evaluating cancer risk in the United States. The company offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion genomic test that helps physicians better assess risk of pancreaticobiliary cancers using its PathFinderTG platform; and ThyGeNEXT, an oncogenic mutation panel to identify malignant thyroid nodules. It also provides ThyraMIR assesses thyroid nodules for risk of malignancy utilizing a proprietary microRNA gene-expression assay; and RespriDx, a genomic test that helps physicians to differentiate metastatic or recurrent lung cancer. The company also provides pharmacogenomics testing, genotyping, biorepository, and other customized services to the pharmaceutical and biotech industries. It primarily serves physicians, hospitals, and clinics. The company was formerly known as Interpace Diagnostics Group, Inc. and changed its name to Interpace Biosciences, Inc. in November 2019. Interpace Biosciences, Inc. was incorporated in 1986 and is headquartered in Parsippany, New Jersey.

Receive IDXG Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Interpace Biosciences and its competitors with MarketBeat's FREE daily newsletter.

IDXG Stock News Headlines

PDI: Beware The Massive NAV Premium
Interpace Biosciences Inc.
When it comes to NVDA… “acceleration cycles” are the key
Expert options trader Graham Lindman has been working on a new way to tap into Nvidia’s options… By simply isolating outsized “acceleration cycles” within Nvidia stock (most investors don’t even know it exists)... And thanks to many months and late nights working out the kinks of the systems… They have finally found a way to target these cycles on Nvidia over and over again.
Interpace Biosciences Reports Impressive Q3 2024 Growth
PDI: The Big ROC Bath, 13.5% 'Yield'
Healthcare Stocks Pre-Market Movers
See More Headlines

IDXG Stock Analysis - Frequently Asked Questions

Interpace Biosciences, Inc. (NASDAQ:IDXG) released its quarterly earnings results on Wednesday, March, 29th. The business services provider reported ($0.33) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.07) by $0.26. The business services provider had revenue of $8.33 million for the quarter. Interpace Biosciences had a negative trailing twelve-month return on equity of 8.09% and a net margin of 10.39%.

Based on aggregate information from My MarketBeat watchlists, some other companies that Interpace Biosciences investors own include Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE), Advanced Micro Devices (AMD), Dynavax Technologies (DVAX), Bristol-Myers Squibb (BMY), Novavax (NVAX) and Histogenics (HSGX).

Company Calendar

Last Earnings
3/29/2023
Today
11/21/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
Health Care Services
Current Symbol
NASDAQ:IDXG
CUSIP
69329V10
Employees
152
Year Founded
N/A

Profitability

Net Income
$800,000.00
Pretax Margin
10.93%

Debt

Sales & Book Value

Annual Sales
$40.21 million
Cash Flow
$0.63 per share
Book Value
($13.11) per share

Miscellaneous

Free Float
4,157,000
Market Cap
$11.79 million
Optionable
Not Optionable
Beta
0.62
5G Stocks: The Path Forward is Profitable Cover

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

This page (NASDAQ:IDXG) was last updated on 11/21/2024 by MarketBeat.com Staff
From Our Partners